Oxford BioMedica PLC
LSE:OXB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oxford BioMedica PLC
Total Receivables
Oxford BioMedica PLC
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Receivables
£65.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
18%
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Receivables
$35.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Receivables
£75.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Receivables
$15.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Receivables
£124.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Niox Group PLC
LSE:NIOX
|
Total Receivables
£5.4m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-10%
|
|
Oxford BioMedica PLC
Glance View
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
See Also
What is Oxford BioMedica PLC's Total Receivables?
Total Receivables
65.2m
GBP
Based on the financial report for Dec 31, 2025, Oxford BioMedica PLC's Total Receivables amounts to 65.2m GBP.
What is Oxford BioMedica PLC's Total Receivables growth rate?
Total Receivables CAGR 10Y
18%
Over the last year, the Total Receivables growth was 18%. The average annual Total Receivables growth rates for Oxford BioMedica PLC have been 4% over the past three years , 5% over the past five years , and 18% over the past ten years .
